Here are 1-3 brief analogies for Medpace (MEDP):

• The AWS for drug and medical device clinical trials.
• Accenture for pharmaceutical and medical device R&D.

• Clinical Development & Monitoring: Comprehensive management and oversight of clinical trials for drugs and medical devices from Phase I through Phase IV.
• Regulatory Affairs: Expert guidance and support for navigating global regulatory processes and preparing submissions for market authorization.
• Data Management & Biostatistics: Collection, processing, analysis, and reporting of clinical trial data to derive meaningful insights.
• Pharmacovigilance: Systematic monitoring and reporting of adverse drug reactions to ensure patient safety throughout the product lifecycle.
• Central Laboratory Services: Standardized and coordinated laboratory testing, sample management, and bio-analytical services for clinical studies.
• Specialized Imaging & ECG: Provision of advanced medical imaging and electrocardiography reading support for clinical trials.

Medpace (MEDP) provides clinical research and development services primarily to other companies in the life sciences sector. Medpace serves a broad and diversified client base, and as such, no single customer typically accounts for a significant portion of its revenue (e.g., 10% or more) that would require individual disclosure in its public filings. Therefore, specific names of major customer companies are not publicly available.

Instead, Medpace's customer base can be categorized into the following industries:

• Pharmaceutical Companies: This includes a range of clients from large, established global pharmaceutical corporations to emerging small and mid-sized drug developers that require clinical trial services for their drug candidates.
• Biotechnology Companies: Often innovative and rapidly growing firms focused on developing biological products and therapies, these companies frequently outsource their clinical development needs to Contract Research Organizations (CROs) like Medpace.
• Medical Device Companies: Organizations engaged in the development, manufacturing, and marketing of medical devices also utilize Medpace's services for clinical trials, regulatory support, and post-market studies.

1. Dependence on Biopharmaceutical R&D Spending, Funding, and Project Cancellations: Medpace's revenue is heavily reliant on the research and development (R&D) expenditures of pharmaceutical, biotechnology, and medical device companies, particularly smaller biopharmaceutical firms which accounted for 79% of its net revenue in 2024. These companies may have limited access to capital, making Medpace susceptible to a slowdown in biotech funding or reduced R&D budgets. A soft biotech funding environment, as observed since 2022, and higher interest rates affecting industry funding, can lead to decreased demand for Medpace's services. Furthermore, cancellations and delays in clinical trials negatively impact Medpace's operating results, with the company reporting a higher level of cancellations and a historically low net book-to-bill ratio in the third quarter of 2024 and Q4 2025.
2. Regulatory Changes and Compliance Risks: Medpace operates in a highly regulated industry, making it vulnerable to healthcare reform and potential additional regulatory changes that could impact the biopharmaceutical industry. Such reforms might reduce the need for Medpace's services or negatively affect its profitability. Recent legislation mandating medicine price cuts in the U.S. and reductions in U.S. government healthcare expenses pose a considerable risk, as they could lead customers to reduce R&D expenditures. Any failure to comply with stringent regulatory requirements, such as Good Clinical Practice (GCP) regulations, could result in significant liabilities, including the need to repeat clinical trials, thereby affecting the company's financial performance and reputation.
3. Intense Industry Competition and Pricing Pressure: The clinical research organization (CRO) industry is highly competitive and characterized by rapid consolidation and the emergence of new competitors. Medpace must continuously innovate and differentiate its services to maintain its market position against larger or more specialized CROs. This competitive landscape can lead to increased pricing pressure or other pressures, which could result in a decrease in Medpace's operating margins if the company is unable to achieve efficiencies or grow revenues at a rate faster than expenses.

The increasing adoption of artificial intelligence (AI) and machine learning (ML) by pharmaceutical and biotechnology companies for drug discovery, clinical trial design, patient recruitment, and data analysis represents a clear emerging threat. This technology can enable sponsors to perform more tasks in-house or rely on specialized AI-driven platforms, potentially reducing the scope or volume of traditional outsourced services provided by Contract Research Organizations (CROs) like Medpace. It also opens the door for new, tech-first competitors that leverage AI more effectively in clinical development.

The acceleration and mainstream adoption of decentralized clinical trials (DCTs) and virtual trial models also represent a clear emerging threat. These models shift away from traditional site-centric operations towards remote patient monitoring, telemedicine, wearables, and direct-to-patient services. If Medpace does not rapidly and effectively integrate and scale these technology-driven operational models, it risks losing market share to competitors (both established and new tech-focused players) that are more agile in implementing DCTs, potentially diminishing the demand for Medpace's traditional labor-intensive monitoring and site management services.

Medpace Holdings, Inc. (MEDP) operates within the Contract Research Organization (CRO) industry, providing a comprehensive suite of clinical research-based drug and medical device development services across various therapeutic areas globally, including North America, Europe, and Asia. These services span the entire clinical development process from Phase I to Phase IV.

According to Medpace's corporate presentation from May 2025, their core addressable market for the services they provide is estimated to be $71 billion globally. With a specific emphasis on serving small to mid-sized biotechnology, pharmaceutical, and medical device companies, this addressable market is clarified to be $29 billion globally. Medpace's strategic focus is on these smaller biopharma clients, with 81% of their year-to-date 2025 revenue coming from this segment.

For broader context, the global contract research organization (CRO) services market, which encompasses Medpace's main products and services, was valued at approximately USD 77.00 billion in 2025 and is projected to grow to around USD 149.34 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 7.61% from 2025 to 2034. Other estimates for the global CRO market in 2025 range from USD 84.61 billion to USD 92.27 billion.

Regionally, North America is a significant market for CRO services, holding the largest share of the global market. In 2024, North America accounted for 35% of the global market. Its market size was valued at USD 49.88 billion in 2026. The European CRO market is projected to grow from USD 23.6 billion in 2024 to USD 44.81 billion by 2035. The Asia-Pacific CRO market is estimated at USD 18.94 billion in 2025 and is expected to reach USD 31.10 billion by 2030.

Expected Drivers of Future Revenue Growth for Medpace (MEDP)

1. Conversion of Robust Backlog into Revenue: Medpace consistently highlights its significant backlog of awarded projects. For instance, as of December 31, 2025, approximately $1.9 billion of the company's nearly $3 billion backlog was projected to convert into revenue within the subsequent 12 months. This strong existing pipeline provides a predictable base for future revenue generation.
2. Continued Growth in Net New Business Awards: The company's ability to secure new contracts, evidenced by its net new business awards and book-to-bill ratio, is a crucial indicator of future revenue. Medpace reported $736.6 million in net new business awards in Q4 2025, resulting in a healthy net book-to-bill ratio of 1.04x for the quarter and 1.05x for the full year 2025. A sustained book-to-bill ratio above 1.0 indicates continued expansion of its project pipeline.
3. Enhanced Operational Efficiency and Productivity: Medpace emphasizes ongoing improvements in operational efficiency and productivity. These efforts are expected to optimize resource utilization, allowing the company to execute projects more efficiently and handle increasing demand, thereby contributing to revenue growth without a proportional increase in costs. The company also noted a modest headcount growth alongside substantial revenue growth, suggesting productivity improvements.
4. Sustained Demand for Outsourced, Complex Clinical Trials: Medpace's business model is centered on providing services for complex clinical trials across various therapeutic areas, including cutting-edge cell therapy work. The broader long-term need for outsourced clinical research, particularly for specialized and faster-burning studies, underpins the company's revenue acceleration. While there have been some shifts and elevated cancellations in metabolic trials, management expects a normalization of these trends, supporting overall demand for their services.
5. Stable Funding Environment and Request for Proposal (RFP) Flow: Management commentary suggests a stable funding environment for clinical research and anticipates stable to improved RFP flow. A consistent and robust flow of new project requests is essential for replenishing the backlog and driving future revenue growth.

Share Repurchases

• Medpace authorized an additional $1 billion share repurchase program in May 2025.
• For the full year 2025, the company repurchased 2,961,924 shares for a total of $912.9 million.
• As of December 31, 2025, Medpace had $821.7 million remaining under its authorized share repurchase program.

Share Issuance

• Medpace Holdings' shares outstanding declined by 7.77% in 2025 to 0.03 billion, indicating that share repurchases outpaced any issuances.
• In 2024, shares outstanding increased by 0.54% from 2023 to 0.032 billion.
• Stock-based compensation expense, a source of potential dilution, was $34.786 million in 2025 and $25.514 million in 2024.

Capital Expenditures

• Property and equipment expenditures were $31.356 million in 2025 and $36.548 million in 2024.
• Capital expenditures were $36.65 million in 2023 and $36.88 million in 2022.
• The primary focus of capital expenditures is on infrastructure investments in facilities, equipment, and technology.